Drug Development - MM+M - Medical Marketing and Media

Drug Development

All articles by Drug Development

Did the market overreact to Biogen’s Alzheimer’s data?
Did the market overreact to Biogen’s Alzheimer’s data?
Lauren Evans
July 10, 2018
3:49 pm

Biogen’s recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.

Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk
Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk
Alison Kanski
May 16, 2018
9:07 pm

Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.

The infectious disease doctor mining the microbiome for drugs
The infectious disease doctor mining the microbiome for drugs
Laura Entis
March 15, 2018
4:50 pm

How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.

Has DTC in the oncology space kept up with science?
Has DTC in the oncology space kept up with science?
Larry Dobrow
March 8, 2018
12:00 pm

As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.

Five things for pharma marketers to know: Wednesday, February 21, 2018
Five things for pharma marketers to know: Wednesday, February 21, 2018
Lauren Evans
February 21, 2018
4:02 pm

AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.

Five things for pharma marketers to know: Wednesday, February 14, 2018
Five things for pharma marketers to know: Wednesday, February 14, 2018
Frank Washkuch
February 14, 2018
4:06 pm

IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer’s drug.

New tactics change clinical trial awareness game
New tactics change clinical trial awareness game
Sarah Mahoney
January 17, 2018
12:00 pm

Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn’t overwhelm trial organizers.

Five things for pharma marketers to know: Thursday, January 11, 2018
Five things for pharma marketers to know: Thursday, January 11, 2018
Virginia Lau
January 11, 2018
3:20 pm

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Five things for pharma marketers to know: Friday, December 8, 2017
Five things for pharma marketers to know: Friday, December 8, 2017
Virginia Lau
December 8, 2017
3:20 pm

FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance

First ‘Digital Drug’ Faces a Second Litmus Test: Improving Adherence
First ‘Digital Drug’ Faces a Second Litmus Test: Improving Adherence
Marc Iskowitz
November 20, 2017
3:55 pm

Technology like this could expand further to form better collaborations between pharma, payers and organized providers.

  • Culture drives the company

    Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.

  • From Our Partners